Abstract
Updates1 March 1998Update in EndocrinologyJanet A. Schlechte, MD and Robert Kreisberg, MDJanet A. Schlechte, MDFrom the University of Iowa, Iowa City, Iowa; and Baptist Health System, Birmingham, Alabama.Search for more papers by this author and Robert Kreisberg, MDFrom the University of Iowa, Iowa City, Iowa; and Baptist Health System, Birmingham, Alabama.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-5-199803010-00007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Advances in endocrinology in 1996 occurred in many areas. First, another drug was added to the growing list of agents used to treat type 2 diabetes mellitus. Second, an additional agent was found to be effective in decreasing low-density lipoprotein (LDL) cholesterol and triglyceride levels and thus may provide more effective prevention of atherosclerotic vascular disease. Third, the bisphosphonates, especially the oral drug alendronate, were shown to benefit patients with a broad array of bone diseases. In addition, 1996 was a year of studies that contributed to the debate over the use of human growth hormone. Finally, estrogen therapies were ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
